

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2022-23

Date: 15.11.2022

To

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Company Number: 531146

Sub. : Copy of Publication for Un-Audited Financial Results for the quarter and half year ended on September 30, 2022

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2022 approved by the Board of Directors at their Meeting held on 11.11.2022.

The copy of the results published in the Financial Express and Jansatta dated November 12, 2022 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Half Year ended on 30.09.2022 (In Lakhs)

Sl. No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Half year ended		Year Ended	Quarter Ended		Half year ended		Year Ended
		Un-audited 30.09.2022	Un-audited 30.09.2021	Un-audited 30.09.2022	Un-audited 30.09.2021	Audited 31.03.2022	Un-audited 30.09.2022	Un-audited 30.09.2021	Un-audited 30.09.2022	Un-audited 30.09.2021	Audited 31.03.2022
1	Total income from operations (net)	3405.70	3299.65	6810.73	6060.55	11716.53	3405.69	3299.65	6810.72	6060.55	11716.53
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	414.91	505.32	847.41	979.90	1810.35	414.19	505.32	846.69	979.90	1809.42
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	414.91	505.32	847.41	979.90	1810.35	414.19	505.32	846.69	979.90	1809.42
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	361.12	422.18	719.68	837.32	1490.64	360.40	422.18	718.96	837.32	1489.71
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	361.12	422.18	719.68	837.32	1490.64	360.40	422.18	718.96	837.32	1489.71
6	Equity Share Capital	1265.11	1221.66	1265.11	1221.66	1221.66	1265.11	1221.66	1265.11	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)										
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)										
	Basic:	2.85	3.46	5.69	6.85	12.20	2.85	3.46	5.68	6.85	12.19
	Diluted:	2.85	3.46	5.69	6.85	12.20	2.85	3.46	5.68	6.85	12.19

Note:

- The Un-audited financial results for the quarter and half year ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11.11.2022
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities which is visible from increased finance cost. The company has also recruited and placed senior human resources for the purpose of creating its own marketing network in francophone Africa. The company shall start reaping its benefits from next financial year.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place : New Delhi
Date : 11.11.2022

JHAJJAR POWER LIMITED

(An Apraava Energy Company)

Registered Office: Unit No. T-15 B, Salcon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel.: +91 11 6612 0700; Fax: +91 11 6612 0777 / 778

Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099

Tel.: +91 22 6758 8888; Fax: +91 22 6758 8811 / 8833

Website: www.clpgroup.com, www.apraava.com

CIN: U40104DL2008SGC374107



E N E R G Y

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2022

(All amount in Rs. Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half-year ended		Year ended
		30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
1	Total Income from Operations	120,103	94,439	95,706	214,542	182,209	345,597
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,689	1,152	4,991	2,841	9,610	19,186
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,689	1,152	4,991	2,841	9,610	(8,844)
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	288	919	3,789	1,207	7,341	(6,879)

के बाद)												
5. अयुधि के लिए कुल व्यापक आय [अयुधि के लिए (कर के बाद) लाभ/ (हानि) तथा अन्य व्यापक आय (कर के बाद) को शामिल करके]	(470.75)	604.75	8489.30	(717.30)	840.60	12765.94	134.00	10165.03	123.30	15412.71	8651.05	13111.17
6. भुगतान इक्विटी शेयर पूंजी (शेयर का अंकित मूल्य 10/- रु. प्रति) लेखाकन वर्ष	1521.01	1521.01	1518.84	1521.01	1521.01	1518.84	1521.01	1518.84	1521.01	1518.84	1521.01	1521.01
7. आय प्रति शेयर (रु. 10/- प्रति का) (जारी तथा बंद प्रचालनों के लिए) (वार्षिक नहीं)												
मूल व तनुकृत	0.98	1.05	(0.76)	(0.64)	2.60	27.40	2.03	(1.55)	1.96	33.00	(1.89)	27.43

टिप्पणी: उपरोक्त विवरण सेबी (आपत्तियों के सूचीकरण एवं प्रकृटीकरण अपेक्षाएं) विनियमों, 2015 के विनियम 33 के अंतर्गत शेयर बाजार में दाखिल किए गए वित्तीय परिणामों के विस्तृत प्रारूप का सार है। वित्तीय परिणामों का संपूर्ण विवरण शेयर बाजार की वेबसाइट www.bseindia.com तथा कम्पनी की वेबसाइट: www.sabindustries.in पर भी उपलब्ध है।

स्थान: चंडीगढ़
तिथि: 11.11.2022

ह./- संजय गगं
अति. प्रबंध निदेशक



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Half Year ended on 30.09.2022 (In Lakhs)

Sl. No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Half year ended		Year Ended	Quarter Ended		Half year ended		Year Ended
		Un-audited 30.09.2022	Un-audited 30.09.2021	Un-audited 30.09.2022	Un-audited 30.09.2021	Audited 31.03.2022	Un-audited 30.09.2022	Un-audited 30.09.2021	Un-audited 30.09.2022	Un-audited 30.09.2021	Audited 31.03.2022
1	Total income from operations (net)	3405.70	3299.65	6810.73	6060.55	11716.53	3405.69	3299.65	6810.72	6060.55	11716.53
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	414.91	505.32	847.41	979.90	1810.35	414.19	505.32	846.69	979.90	1809.42
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	414.91	505.32	847.41	979.90	1810.35	414.19	505.32	846.69	979.90	1809.42
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	361.12	422.18	719.68	837.32	1490.64	360.40	422.18	718.96	837.32	1489.71
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	361.12	422.18	719.68	837.32	1490.64	360.40	422.18	718.96	837.32	1489.71
6	Equity Share Capital	1265.11	1221.66	1265.11	1221.66	1221.66	1265.11	1221.66	1265.11	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)										
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)										
	Basic:	2.85	3.46	5.69	6.85	12.20	2.85	3.46	5.68	6.85	12.19
	Diluted:	2.85	3.46	5.69	6.85	12.20	2.85	3.46	5.68	6.85	12.19

Note:

- The Un-audited financial results for the quarter and half year ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11.11.2022
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -Earning per Share
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities which is visible from increased finance cost. The company has also recruited and placed senior human resources for the purpose of creating its own marketing network in francophone Africa. The company shall start reaping its benefits from next financial year.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place : New Delhi
Date : 11.11.2022